Trials / Recruiting
RecruitingNCT06673498
Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery
Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery: a Prospective, Multicentre, Single-arm Clinical Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Anhui Provincial Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of lusutrombopag combined with recombinant human thrombopoietin for the treatment of thrombocytopenia in patients with chronic liver disease destined to undergo elective invasive surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lusutrombopag combined with recombinant human thrombopoietin | After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days |
Timeline
- Start date
- 2024-11-10
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
- First posted
- 2024-11-05
- Last updated
- 2024-11-05
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06673498. Inclusion in this directory is not an endorsement.